Supplemental Figure S3. Visual predictive check plots with overlaid observations for the updated population plasma pharmacokinetic models by non-ESRD renal function groups on a logarithmic scale (panel A: ceftolozane; panel B: tazobactam) and ESRD renal function group (panel C: ceftolozane; panel D: tazobactam). Renal function groups are as indicated. CI, confidence interval; CrCL, creatinine clearance; ESRD, end-stage renal disease.
Supplemental Figure S3 continued

B

Tazobactam

CrCL [250, 531] mL/min

CrCL [210, 250] mL/min

CrCL [180, 210] mL/min

CrCL [150, 180] mL/min

CrCL [80, 150] mL/min

CrCL [50, 80] mL/min

CrCL [30, 50] mL/min

CrCL [15, 29] mL/min

Data: +
Observations

Median: 小
5th and 95th percentiles: 大

Predictions: 小
Median: 小
5th and 95th percentiles: 大

95% CI of prediction percentiles

Tazobactam concentration (μg/mL)
Time since previous dose (hours)
Supplemental Figure S3 continued

C

**Cefoxitin ESRD**

- Data: + Observations
- Predictions: Median, 5th and 95th percentiles
- 95% CI of prediction percentiles

D

**Tazobactam ESRD**

- Data: + Observations
- Predictions: Median, 5th and 95th percentiles
- 95% CI of prediction percentiles